RE: RNS11 Dec 2020 13:28
The viability of getting the product onto the market in the US does not seem to be in question in my view, it's a case of either it taking longer than hoped for a solid licensing arrangement, or engaging in a riskier and more time-consuming -- but very lucrative -- direct launch.
On that basis, I think the SP decline is majorly overdone. Of course, given that the timelines have likely shifted in terms of major profitability and various risks have increased, it is understandable there has been a decline.
The fact major shareholders have offered soft loans is really a sign of very significant confidence that this can be cracked.
I think some good points were made earlier about the proposed direct launch strategy -- it does provide a hedge to ensure that more attractive terms are made in licensing, as we have a credible alternative (and to ensure seriousness from counter-parties).
Anyway, I'm as disappointed as anyone else. Certainly the first thought hit me was, "yet another AIM company failing to meet its guidance; nada cambia". But, the proposed strategy seems credible to me, and there is a very long runway to ensure execution (aside from potential income from existing arrangements, of course).
Naturally, the leadership team is going to need to repair market confidence after making strong guidance and missing it rather spectacularly. Fundamentally, I am going to keep holding, a very red paper position right now.